Payment overview · 2025
General Payments
$368.38
16 reported records · 6 companies
Healthcare provider profile · identity verified
Morgan Robert Poncy, MD
Allopathic & Osteopathic Physicians|Internal Medicine · JUPITER, FL · NPI 1891716056
Verified facts
What the public records show
CMS Open Payments records show Morgan Robert Poncy, MD received $368.38 in general payments during 2025 across 16 reported records.
Novartis Pharmaceuticals Corporation accounted for 40.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Paxlovid.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GENOTROPIN as an associated drug or biological on 864 records involving 515 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Genotropin by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $147.81 | 40.1% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $72.04 | 19.6% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $55.83 | 15.2% | 3 | 2025 |
| Cleerly, Inc. | Unresolved — no canonical attribution shown | $47.49 | 12.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.53 | 6.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.68 | 5.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $368.38 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $147.81 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $72.04 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $72.04 | 3 | 2025 |
Source payment records
|
|||||
| Cleerly Ischemia Normalized: cleerly ischemia |
Device | Cleerly, Inc. | $47.49 | 2 | 2025 |
Source payment records
|
|||||
| Cleerly Labs Normalized: cleerly labs |
Device | Cleerly, Inc. | $47.49 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $41.44 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $24.53 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $24.53 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.68 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.68 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 162 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 82 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 44 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
162 | 22 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
82 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
70 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | GENOTROPIN open payments reported associated product |
CMS Open Payments — General Payments 864 supporting records · 515 recipient NPIs · example record 1228794127 |
Genotropin · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
44 | 42 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 609 | 183 |
| Methylprednisolone | Methylprednisolone | 323 | 199 |
| Azithromycin | Azithromycin | 274 | 181 |
| Levothyroxine Sodium | Levothyroxine Sodium | 239 | 74 |
| Atorvastatin Calcium | Atorvastatin Calcium | 170 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 168 | 49 |
| Mounjaro | Tirzepatide | 162 | 22 |
| Alprazolam | Alprazolam | 152 | 48 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 139 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 136 | 42 |
| Losartan Potassium | Losartan Potassium | 118 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 117 | 39 |
| Prednisone | Prednisone | 116 | 64 |
| Montelukast Sodium | Montelukast Sodium | 95 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 85 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 83 | 41 |
| Ozempic | Semaglutide | 82 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 78 | 27 |
| Celecoxib | Celecoxib | 71 | 23 |
| Eliquis | Apixaban | 70 | 24 |
| Allopurinol | Allopurinol | 65 | 21 |
| Xarelto | Rivaroxaban | 62 | 14 |
| Repatha Sureclick | Evolocumab | 61 | 12 |
| Metformin Hcl | Metformin Hcl | 60 | 21 |
| Meloxicam | Meloxicam | 59 | 18 |
| Lisinopril | Lisinopril | 57 | 15 |
| Ezetimibe | Ezetimibe | 52 | 15 |
| Synthroid | Levothyroxine Sodium | 52 | 16 |
| Tramadol Hcl | Tramadol Hcl | 50 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 44 | 42 |
| Omeprazole | Omeprazole | 42 | 14 |
| Diazepam | Diazepam | 40 | 13 |
| Repatha Syringe | Evolocumab | 39 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 36 | 12 |
| Simvastatin | Simvastatin | 35 | 11 |
| Lorazepam | Lorazepam | 34 | 15 |
| Gabapentin | Gabapentin | 32 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 14 |
| Candesartan Cilexetil | Candesartan Cilexetil | 28 | suppressed |
| Cephalexin | Cephalexin | 28 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Furosemide | Furosemide | 26 | 11 |
| Potassium Chloride | Potassium Chloride | 26 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 25 | suppressed |
| Genotropin | Somatropin | 24 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 24 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 16 |
| Estradiol | Estradiol | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Carvedilol | Carvedilol | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 14 |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 16 | suppressed |
| Minoxidil | Minoxidil | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 13 |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Dupixent Pen | Dupilumab | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Darifenacin Er | Darifenacin Hydrobromide | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $368.38 · 16 records | Novartis Pharmaceuticals Corporation | Cleerly Ischemia, Cleerly Labs, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, REPATHA, Wegovy, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error